Table 2.
Rate of adjuvant trastuzumab therapy in HER2-positive patients.
| Year of diagnosis | Total number of HER2-positive patients (N) | Trastuzumab received | ||
|---|---|---|---|---|
| Total | Premenopausal | Postmenopausal | ||
| 2000 | 21 | 0/21 (0%) | 0/10 (0%) | 0/11 (0%) |
| 2001 | 83 | 1/83 (1%) | 0/19 (0%) | 1/64 (2%) |
| 2002 | 79 | 2/79 (3%) | 2/22 (9%) | 0/57 (0%) |
| 2003 | 99 | 2/99 (2%) | 1/28 (4%) | 1/71 (1%) |
| 2004 | 95 | 2/95 (2%) | 0/26 (0%) | 2/69 (3%) |
| 2005 | 97 | 34/97 (35%) | 11/23 (48%) | 23/74 (31%) |
| 2006 | 110 | 42/110 (38%) | 18/31 (58%) | 24/79 (30%) |
| 2007 | 97 | 57/97 (59%) | 15/19 (79%) | 42/78 (54%) |
| 2008 | 90 | 53/90 (59%) | 15/19 (79%) | 38/71 (54%) |
| 2009 | 117 | 64/117 (55%) | 21/33 (64%) | 43/84 (51%) |
| 2010 | 114 | 65/114 (57%) | 19/29 (66%) | 46/85 (54%) |
| 2011 | 65 | 43/65 (66%) | 20/22 (91%) | 23/43 (54%) |
| 2012 | 67 | 24/67 (36%) | 11/24 (46%) | 13/43 (30%) |
|
| ||||
| Total | 1134 | 389/1134 (34%) | 133/305 (44%) | 256/829 (31%) |